PT  - JOURNAL ARTICLE
AU  - Fröberg, Janeri
AU  - Gillard, Joshua
AU  - Philipsen, Ria
AU  - Lanke, Kjerstin
AU  - Rust, Joyce
AU  - van Tuijl, Diana
AU  - Bousema, Teun
AU  - Simonetti, Elles
AU  - van der Gaast – de Jongh, Christa E.
AU  - Bos, Mariska
AU  - van Kuppeveld, Frank J.
AU  - Bosch, Berend-Jan
AU  - Nabuurs-Franssen, Marrigje
AU  - van der Geest-Blankert, Nannet
AU  - van Daal, Charlotte
AU  - Huynen, Martijn A.
AU  - de Jonge, Marien I.
AU  - Diavatopoulos, Dimitri A.
TI  - Elevated mucosal antibody responses against SARS-CoV-2 are correlated with lower viral load and faster decrease in systemic COVID-19 symptoms
AID  - 10.1101/2021.02.02.21250910
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.02.21250910
4099  - http://medrxiv.org/content/early/2021/02/03/2021.02.02.21250910.short
4100  - http://medrxiv.org/content/early/2021/02/03/2021.02.02.21250910.full
AB  - Mucosal antibodies play a key role in protection against SARS-CoV-2 exposure, but their role during primary infection is not well understood. We assessed mucosal antibody responses during primary infection with SARS-CoV-2 and examined their relationship with viral load and clinical symptoms. Elevated mucosal IgM was associated with lower viral load. RBD and viral spike protein-specific mucosal antibodies were correlated with decreases in systemic symptoms, while older age was associated with an increase in respiratory symptoms. Up to 42% of household contacts developed SARS-CoV-2-specific mucosal antibodies, including children, indicating high transmission rates within households in which children might play an important role.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04590352Funding StatementThis study was funded by the Laboratory of Medical Immunology, Radboud university medical center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Arnhem-Nijmegen Medical Ethical Committee, is registered at clinicaltrials.gov (NCT04590352; ethical committee reference NL73418.091.20), and was performed in accordance with the declaration of Helsinki. Written informed consent was obtained from volunteers before any research procedure was initiated.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and R-code that support the findings of this study are available from the corresponding author upon reasonable request.